Retatrutide vs Tirzepatide vs Semaglutide: Mounjaro, Ozempic, Zepbound & Wegovy Compared

Semaglutide activates GLP-1 receptors, tirzepatide activates GLP-1 and GIP receptors, and retatrutide activates GLP-1, GIP, and glucagon receptors. Their trials differ in population, duration, and analysis. No trial has compared all three together; more receptors does not by itself prove better treatment.

This page breaks down the comparison with data from the published trials, along with the caveats you need to interpret that data fairly.

Side-by-Side Comparison

How the Mechanisms Differ: Single vs Dual vs Triple Agonism

All three drugs belong to the same family — they mimic gut hormones called incretins to regulate appetite, blood sugar, and metabolism. The difference is how many hormone receptors each drug activates.

Semaglutide: GLP-1 Only

Semaglutide targets a single receptor: GLP-1. This reduces appetite, slows gastric emptying (so you feel full longer), and improves insulin secretion. GLP-1 agonism is the foundation of this entire drug class and remains highly effective on its own.

Tirzepatide: GLP-1 + GIP

Tirzepatide adds a second target: GIP (glucose-dependent insulinotropic polypeptide). GIP complements GLP-1 by further stimulating insulin release and may have additional effects on fat metabolism. In head-to-head trials, tirzepatide outperformed semaglutide for both weight loss and blood sugar control.

Retatrutide: GLP-1 + GIP + Glucagon

Glucagon receptor activation is being studied for effects on energy expenditure and hepatic fat metabolism. Preclinical studies support this rationale, but the human trials do not isolate how much weight loss each receptor contributes. Counting receptor targets cannot establish which drug is better.

Weight Loss Comparison

This is what most people want to know. Here are the headline numbers from the pivotal trials of each drug.

Peak Weight Loss by Drug

*TRIUMPH-4 enrolled participants with obesity and knee osteoarthritis specifically.

Weight Loss Thresholds (Percentage of Participants Achieving Each Level)

The threshold data for retatrutide TRIUMPH-4 was reported at the 25% and 30% levels, reflecting the higher overall weight loss in this trial. Direct threshold-to-threshold comparisons with semaglutide and tirzepatide should be made cautiously — see the caveats section below.

Why You Cannot Directly Compare These Numbers

These are not results from a single head-to-head study. Each number comes from a different trial, with different:

• Populations: STEP 1 and SURMOUNT-1 enrolled general obesity populations. TRIUMPH-4 enrolled people with obesity and knee osteoarthritis.
• Durations: 48 weeks (Phase 2 retatrutide), 68 weeks (STEP 1, TRIUMPH-4), 72 weeks (SURMOUNT-1).
• Trial phases: Phase 2 trials are smaller and often produce more favorable results than Phase 3 trials.
• Sample sizes: The Phase 2 retatrutide trial had 338 participants versus 1,961 (STEP 1) and 2,539 (SURMOUNT-1).
• Placebo responses: Placebo weight loss varied across trials.
• Baseline characteristics: Starting weight, age, and comorbidities differed.

The selected trial averages are numerically different, but they do not measure the effect of adding receptors. A direct comparison is needed to establish the difference between treatments.

Diabetes Management Comparison

All three drugs significantly reduce HbA1c (a measure of average blood sugar over 2-3 months) in people with type 2 diabetes.

Side Effects Comparison

The side effect profiles of all three drugs are broadly similar, dominated by gastrointestinal (GI) symptoms. This is expected — GLP-1 agonism slows gastric emptying, and GI symptoms are the main tolerability issue across the entire drug class.

Common Side Effects

For all three drugs, GI side effects are most common during dose escalation and tend to improve over time. The gradual dose-titration protocols used in clinical trials are specifically designed to minimize these effects.

Notable Differences

• Semaglutide has the longest real-world safety track record, with millions of patients treated since 2017.
• Tirzepatide has a growing real-world safety profile since 2022 and has been generally well-tolerated.
• Retatrutide: Dysesthesia (altered skin sensation) occurred in 8.8% and 20.9% of the retatrutide 9 mg and 12 mg groups in TRIUMPH-4. It is not unique to retatrutide: current Wegovy and Zepbound labels also report it. A glucagon-specific cause has not been established.

Unique Advantages of Each Drug

Semaglutide

• Longest track record: Approved since 2017, with extensive real-world data and post-marketing surveillance.
• Oral options: Rybelsus is used for diabetes and oral Wegovy for weight management. Orforglipron (Foundayo) is another oral option, approved in April 2026.
• Coverage: Check the exact product and indication against your insurance formulary; coverage cannot be ranked reliably by molecule.
• Cardiovascular outcomes data: SELECT found a 20% relative reduction in major cardiovascular events with semaglutide in adults with established cardiovascular disease and overweight or obesity, without diabetes. This does not apply to every person with a cardiovascular risk factor.

Tirzepatide

• Stronger weight loss than semaglutide: Consistently produces greater weight loss in trials, including in head-to-head comparisons.
• Diabetes evidence: Mounjaro has an approved diabetes indication; its suitability depends on glycemic goals, other medicines, and tolerability.
• Available now: Unlike retatrutide, tirzepatide is approved and accessible through standard prescriptions and programs like LillyDirect.
• Growing real-world evidence: Over two years of post-approval data supporting its efficacy and safety.

Retatrutide

• Substantial trial weight loss: TRIUMPH-4 reported 28.7% at 68 weeks using the efficacy estimand in adults with overweight or obesity and knee osteoarthritis without diabetes.
• Liver fat research: The retatrutide Phase 2 liver substudy included 98 participants with baseline liver fat of at least 10%. At 12 mg, relative liver fat reduction was 82.4% at 24 weeks and 86.0% at 48 weeks. MRI-measured fat reduction does not establish MASH resolution, fibrosis improvement, or superiority over another drug.
• Additional receptor target: Glucagon receptor activation is being studied for effects on energy expenditure and hepatic fat metabolism. Preclinical studies support this rationale, but the human trials do not isolate how much weight loss each receptor contributes. Counting receptor targets cannot establish which drug is better.
• Potential for osteoarthritis benefit: TRIUMPH-4 demonstrated significant pain relief in participants with knee osteoarthritis.

Liver Fat: Retatrutide's Standout Data Point

Availability and Access

If you are currently interested in incretin-based weight loss treatment, approved options include semaglutide, tirzepatide, and orforglipron. Retatrutide is not available outside of clinical trials. Be cautious of any online source claiming to sell retatrutide — these are unregulated, unverified, and potentially dangerous.

Cost Comparison

Prices vary by brand, dose, insurance coverage, and eligibility for manufacturer programs. Mounjaro and Zepbound contain the same molecule but have different indications and access arrangements. Check the current price for the exact prescription with the pharmacy and manufacturer. Retatrutide has no approved retail price.

Who Might Benefit from Each

These are general considerations, not medical recommendations. Your doctor is the right person to determine which drug is appropriate for you.

Semaglutide may be a good fit if you:

• Want the most established drug with the longest safety track record
• Prefer an oral option (no injections)
• Have established cardiovascular disease and meet the relevant approved indication
• Have coverage for the prescribed formulation and indication
• Are looking for a moderate level of weight loss (~15%)

Tirzepatide may be a good fit if you:

• Want stronger weight loss than semaglutide offers
• Have type 2 diabetes and need an approved glucose-lowering option
• Are comfortable with injectable treatment
• Want an approved drug available today with a strong efficacy profile

Retatrutide may be worth watching if you:

• Have significant liver fat or MASH/NAFLD
• Are interested in the most potent weight loss option once it becomes available
• Have not achieved sufficient results with semaglutide or tirzepatide
• Want to discuss eligibility for a clinical trial

Important Caveats About Comparing Trial Data

This deserves its own section because the comparison numbers are often cited without context.

1. No trial compares all three together. Tirzepatide and semaglutide have been compared directly. Retatrutide versus tirzepatide is being studied in TRIUMPH-5; results were not available at this review.
2. Phase 2 vs Phase 3 matters. Retatrutide's widely-cited 24.2% figure comes from a Phase 2 trial with 338 participants over 48 weeks. Phase 2 trials are smaller and often produce more optimistic results. The Phase 3 TRIUMPH-4 result of 28.7% at 68 weeks is more robust but was conducted in an osteoarthritis population.
3. Different populations, different results. STEP 1 and SURMOUNT-1 enrolled general obesity populations. TRIUMPH-4 enrolled people with obesity and knee osteoarthritis. Population differences affect outcomes.
4. The weight loss curve may not have plateaued. In the Phase 2 retatrutide trial, participants were still losing weight at 48 weeks — the curve had not flattened. This suggests the final weight loss ceiling may be even higher, but it also means the 48-week number is not a final result.
5. Efficacy in trials does not guarantee real-world results. Clinical trial participants receive close monitoring, regular check-ins, and structured support. Real-world adherence is typically lower, and results may be more modest.
6. Individual variation is substantial. Within every trial, some participants lose significantly more than average and some lose less. The "average" result may not reflect your personal outcome.

Frequently Asked Questions

Sources

• FDA. Current Wegovy prescribing information.
• Lilly. Retatrutide Phase 3 program and planned filing.
• Wilding, J.P.H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. DOI: 10.1056/NEJMoa2032183
• Jastreboff, A.M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. DOI: 10.1056/NEJMoa2206038
• Jastreboff, A.M., et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. DOI: 10.1056/NEJMoa2301972
• Rosenstock, J., et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-comparator-controlled, parallel-group, phase 2 trial. The Lancet. DOI: 10.1016/S0140-6736(23)01053-X
• Eli Lilly and Company. (2025). Lilly's retatrutide achieved significant weight loss and pain relief in adults with obesity and knee osteoarthritis. Press release.
• Lincoff, A.M., et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine. DOI: 10.1056/NEJMoa2307563
• ClinicalTrials.gov: NCT04881760, NCT04867785